PPARA and primary biliary cholangitis: Bezafibrate is a pan-PPAR agonist that has been shown to have potent anticholestatic efficacy in PBC patients with an incomplete biochemical response to ursodeoxycholic acid (UDCA) monotherapy (Honda et al., 2013).